OncoMatch/Clinical Trials/NCT05302284
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Is NCT05302284 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for urothelial carcinoma.
Treatment: RC48-ADC · Toripalimab · Gemcitabine · Cisplatin · Carboplatin — This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 1+, 2+ or 3+)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Prior ADCs
Cannot have received: anti-PD-1 therapy
Prior PD-1/PD-L1 inhibitor therapy
Cannot have received: anti-PD-L1 therapy
Prior PD-1/PD-L1 inhibitor therapy
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify